A share price of Vaxcyte Inc [PCVX] is currently trading at $43.7, up 4.07%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PCVX shares have gain 2.44% over the last week, with a monthly amount glided 32.18%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Vaxcyte Inc [NASDAQ: PCVX] stock has seen the most recent analyst activity on September 12, 2025, when Goldman initiated its Neutral rating and assigned the stock a price target of $38. On December 20, 2024, Goldman initiated with a Buy rating and assigned a price target of $135 on the stock. Mizuho started tracking the stock assigning a Buy rating and suggested a price target of $69 on December 07, 2023. TD Cowen initiated its recommendation with a Outperform. Needham reiterated a Buy rating for this stock on January 03, 2023, and upped its price target to $58. In a note dated December 15, 2022, Guggenheim initiated a Buy rating and provided a target price of $66 on this stock.
Vaxcyte Inc experienced fluctuations in its stock price throughout the past year between $27.66 and $118.62. Currently, Wall Street analysts expect the stock to reach $124 within the next 12 months. Vaxcyte Inc [NASDAQ: PCVX] shares were valued at $43.7 at the most recent close of the market. An investor can expect a potential return of 183.75% based on the average PCVX price forecast.
Analyzing the PCVX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.17 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Vaxcyte Inc [NASDAQ:PCVX] is 11.11. Also, the Quick Ratio is 11.11, while the Cash Ratio stands at 1.99.
Transactions by insiders
Recent insider trading involved Eydelman Mikhail, SVP, GEN COUNSEL & CORP SEC, that happened on Mar 05 ’25 when 5000.0 shares were sold. Officer, Eydelman Mikhail completed a deal on Mar 05 ’25 to buy 5000.0 shares. Meanwhile, CHIEF OPERATING OFFICER Wassil Jim sold 8000.0 shares on Mar 03 ’25.
